Abstract

This application is being submitted by Loyola University Chicago, Stritch School of Medicine, Cardinal Bemardin Cancer Center for renewal of the Cancer Center's long standing participation as a site for clinical trials conducted by the Southwest Oncology Group (SWOG). Loyola remains a highly productive member of SWOG, enrolling 667 subjects to SWOG studies over the past five-year cycle. Fourteen members of the Division of Hematology/Oncology faculty are members of SWOG, and two newer faculty members are presently applying for membership. Loyola's Departments of Radiation Therapy, Surgery, Thoracic Surgery, ENT, Gynecology, Pathology, and Neurosurgery are active participants in SWOG-sponsored studies, identifying patients for possible inclusion in the studies and for the subsequent treatment of patients. In addition, Loyola has three affiliate institutions participating in SWPG studies: Good Samaritan Hospital, Downer's Grove IL;St. Mary's Provena Medical Center, Kankakee IL;and Quad Cities CGOP, Davenport IA.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046282-22
Application #
7564736
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1988-01-01
Project End
2009-12-31
Budget Start
2009-01-09
Budget End
2009-12-31
Support Year
22
Fiscal Year
2009
Total Cost
$389,625
Indirect Cost

  Institution

Name
Loyola University Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Maywood
State
IL
Country
United States
Zip Code
60153

  Publications

Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Stiff, Patrick J; Montesinos, Pau; Peled, Tony et al. (2018) Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. Biol Blood Marrow Transplant 24:1463-1470
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Statler, Abby; Othus, Megan; Erba, Harry P et al. (2018) Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood 131:2782-2788
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585

Showing the most recent 10 out of 238 publications